Patent · US Active

Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2

US10935548B2 · kind B2 · utility

0Cited by
50References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 7, 2012
Grant dateMar 2, 2021
Priority date
Expiry dateDec 7, 2032

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/56
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.